IVCA Feature: Accelerating Life Sciences in the Wake of the Pandemic

IVCA Feature: Accelerating Life Sciences in the Wake of the Pandemic

March 3, 2021

Continuing our series on Life Sciences, the main focus in this line of entrepreneurship and innovation in 2020 has concerned, of course. the navigation of the pandemic. Research and development within biotech accelerated as the vaccines were developed, and previous R&D contributed to the success in formulating the preventive medicines as processes sped up during the necessity to rollout a universal remedy. Life sciences has evolved faster in this atmosphere, and seven online articles amplify this trend through the prism of the VC and PE industries.
 
EY.com, ‘How the Pandemic has Changed the Rules for Life Sciences Deals’
 
Setting aside the challenges of doing diligence and closing deals virtually, persistently high valuations for biopharma and medtech targets kept many would-be buyers on the sidelines. If there was any trend that signaled just how much capital was available to biotechs in 2020 it was the rise of special purpose acquisition companies (SPACs), which raised, or announced plans to raise, more than US$3 billion.
 
READ MORE: https://www.ey.com/en_gl/life-sciences/how-the-pandemic-has-changed-the-rules-for-life-sciences-deals
 
Pharmaceutical-Technology.com, ‘What Does 2021 Have in Store for Healthcare Investment?’
 
Silicon Valley Bank (SVB) found that 2020 was a record year for healthcare fundraising, investment and exits. Healthcare investment was more than 47% higher than in 2019 with a new high of $51B being invested in the sector in 2020. Venture capital (VC) fundraising was particularly strong across the sector with $17B available in new venture funds focused on healthcare.
READ HERE: https://www.pharmaceutical-technology.com/features/svv-qanda-healthcare-investment-2021/ 
 
PEnews.com, ‘Healthcare and Life Sciences will Continue to be Private Equity’s focus in 2021’
 
Investors will need to analyze even more closely where the value lies post-pandemic, and not be caught in an investment-entry valuation that will leave them without return in the years ahead. The healthcare and life sciences landscape can be split into three categories, all of which attract a different type of investor: resilient, recovering and refocused businesses.
 
READ HERE: https://www.penews.com/articles/healthcare-and-life-sciences-will-continue-to-be-private-equitys-focus-in-2021-20210111 
 
RopesGray.com, Podcast: ’COVID-19: Pandemic Fundraising Insights and What Lies Ahead for Private Equity in 2021’
 
In this Ropes & Gray podcast, asset management partner Debra Lussier and private capital transactions partner Paul Van Houten interview Tom Burger, managing partner and co-founder of Gridiron Capital. They discuss Gridiron’s experience fundraising during the pandemic, and what lies ahead for private equity in 2021.
LISTEN HERE (13 minutes): https://www.ropesgray.com/en/newsroom/podcasts/2021/January/Podcast-COVID-19-Pandemic-Fundraising-Insights-and-What-Lies-Ahead-for-Private-Equity-in-2021 
 
Soundcloud.com, The Bio Report Podcast: ’How the Pandemic Transformed a Small Diagnostics Company’
 
Case Study: “For more than 15 years, Longhorn Vaccines & Diagnostics has been designing and developing products for potential pandemics in developing economies. The recent COVID-19 pandemic, though, put the scalability of the company’s technology to the test as it landed big contracts in the United States for COVID-19 testing.”
LISTEN HERE (22 minutes): https://soundcloud.com/levine-media-group/how-the-pandemic-transformed-a-small-diagnostics-company
 
FrasierDove.com, ‘Has COVID-19 Accelerated Industry 4.0 in the Life Sciences?’
 
On “Industry 4.0”: “The COVID-19 pandemic has taken the world by storm, but none more so than in the world of manufacturing. Manufacturing is experiencing a period of rapid transformation involving the digitisation and automation of manufacturing processes and procedures. This is none more so evident than in the life sciences industry, which has experienced recent supply chain and manufacturing capacity and continuation issues like never before.”
READ HERE: https://www.fraserdove.com/has-covid-19-accelerated-industry-4-0-in-the-life-sciences/ 
 
The-Scientist.com, ‘Experts Predict the Hottest Life Science Tech in 2021 and Beyond’
 
Overall Perspective: “Through the social and economic disruption that COVID-19 caused in 2020, the biomedical research community rose to the challenge and accomplished unprecedented feats of scientific acumen. With a new year ahead of us, even as the pandemic grinds on, we at THE SCIENTIST thought it was an opportune time to ask what might be on the life science innovation radar for 2021 and beyond.”
READ HERE: https://www.the-scientist.com/news-opinion/experts-predict-the-hottest-life-science-tech-in-2021-and-beyond-68400